Barr generic tamoxifen
Executive Summary
Barr expects answer from FDA in mid-September regarding its right to manufacture generic tamoxifen. Barr is distributing an "authorized" generic of Nolvadex under license from AstraZeneca, and the generic company claims it is entitled to launch its own version before the brand's pediatric exclusivity expires in February. Barr may exhaust its existing inventory of tamoxifen in early November according to one estimate; it appears unlikely AstraZeneca will extend the supply agreement through the pediatric exclusivity period (1"The Pink Sheet" Aug. 26, In Brief)...